Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
eNRGy
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
- NCT02912949 ↗
- Active, not recruiting
- Partner Therapeutics, Inc.
- Deep
We haven't built an HCP commentary report on eNRGy (zenocutuzumab in solid tumors harboring NRG1 fusion) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on eNRGy so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 31 | |
| Podcasts | 4 | |
| YouTube | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion; Pancreatic Cancer Harboring NRG1 Fusion; NRG1 Fusion
- Interventions
- zenocutuzumab (MCLA-128)
- Arms
- Part 2 Pancreatic adenocarcinoma harboring NRG1 fusion · Experimental
- Part 2 NSCLC cancer harboring NRG1 fusion · Experimental
- Part 2 Solid tumour (basket) harboring NRG1 fusion · Experimental
- Enrollment
- 250 (estimated)
- Primary outcomes
- Objective overall response rate (ORR) as per local investigator's assessment
- Duration of response per RECIST v1.1 as per local Investigator's assessment.
- Sponsor
- Partner Therapeutics, Inc.
- Start
- Jan 2015
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT02912949 · updated Apr 29, 2025
Publications
linked from the registry- Cleary JM, Springfeld C, Arnold D, Hollebecque A, Gbolahan O, Nagasaka M, Siena S, Opdam F, Sunakawa Y, Cassier PA, Trikha G, Gort EH, Florou V, Greil R, La Porte PF, Gandhi PJ, Garner F, Wasserman E, Adeyemi S, Schram AM. Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial. J Clin Oncol. 2026 Oct 20;44(30):2908-2918. doi: 10.1200/JCO-25-03128. Epub 2026 Jul 1. PubMed 42385125
- Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A; eNRGy Investigators. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. N Engl J Med. 2025 Feb 6;392(6):566-576. doi: 10.1056/NEJMoa2405008. PubMed 39908431
- Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, Duruisseaux M, Liu SV, Al Hallak MN, Umemoto K, Wesseler C, Cleary JM, Springfeld C, Neuzillet C, Joe A, Jauhari S, Ford J, Goto K. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncol. 2024;20(16):1057-1067. doi: 10.2217/fon-2023-0824. Epub 2024 Feb 13. PubMed 38348690